Organovo (NASDAQ:ONVO) Now Covered by StockNews.com

StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research report released on Friday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Price Performance

ONVO stock opened at $0.35 on Friday. The firm has a 50 day simple moving average of $0.39 and a two-hundred day simple moving average of $0.46. The stock has a market cap of $5.38 million, a PE ratio of -0.33 and a beta of 0.54. Organovo has a one year low of $0.32 and a one year high of $1.74.

Organovo (NASDAQ:ONVO) last issued its earnings results on Friday, November 8th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.12. Organovo had a negative return on equity of 249.28% and a negative net margin of 12,176.70%. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.04 million. On average, research analysts expect that Organovo will post -0.77 EPS for the current fiscal year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.